arrow
M

Mary Ellen Moynahan

Memorial Sloan Kettering Cancer Center
H指数:42
被引数:1.1万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Alterations in PTEN and ESR1 promote clinical resistance to alpelisib plus aromatase inhibitors

PTEN和ESR1的改变促进了对alpelisib加芳香酶抑制剂的临床耐药性

2020-03-23104
OAAI
Phase II trial of veliparib in patients with previously treated BRCA-mutated pancreas ductal adenocarcinoma
2018-01-01131
OAAI
Phase I study of PI3Kα inhibitor BYL719+aromatase inhibitor (AI) in patients (pts) with hormone receptor-positive (HR plus ) metastatic breast cancer (MBC)
2015-08-012
PRE
Phase I trial: PI3Kα inhibitor BYL719 plus aromatase inhibitor (AI) for patients with hormone receptor-positive (HR plus ) metastatic breast cancer (MBC)

I期试验: pi3k α 抑制剂BYL719加芳香化酶抑制剂 (AI) 治疗激素受体阳性 (HR plus) 转移性乳腺癌 (MBC) 患者

2015-05-010
PRE
Phase II Trial of Bicalutamide in Patients with Androgen Receptor-Positive, Estrogen Receptor-Negative Metastatic Breast Cancer
2013-10-01611
OA
A Feasibility Study of Bevacizumab plus Dose-Dense Doxorubicin-Cyclophosphamide (AC) Followed by Nanoparticle Albumin-Bound Paclitaxel in Early-Stage Breast Cancer
2011-05-1525
OAAI